Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant ch
- PDF / 523,669 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 3 Downloads / 183 Views
EPIDEMIOLOGY
Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer Ilana Usiskin1 · Fangyong Li2 · Melinda L. Irwin2 · Brenda Cartmel2,3 · Tara Sanft3,4 Received: 20 August 2020 / Accepted: 20 October 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose Previous work found that lower BMI is associated with a pathologic complete response (pCR) following neoadjuvant chemotherapy for breast cancer. Relative dose intensity (RDI) of chemotherapy is an important marker of treatment tolerability. We hypothesized that patients with low BMI would have higher RDI than patients with high BMI, explaining the mechanism for the association between BMI and pCR. Methods We conducted a retrospective study of women treated with neoadjuvant chemotherapy for stage I-III breast cancer at Yale New Haven Hospital-Smilow Cancer Hospital. We reviewed medical records to determine tumor characteristics, chemotherapy doses, and reasons for dose reductions or delays. The treatment RDI was calculated using published methods. Chi-squared analyses were conducted to determine the associations between RDI and BMI and between RDI and pCR. Results Our cohort (n = 237) had an average age of 53 years (SD 13) and mean BMI of 29.5 kg/m2 (SD 7.0). Fifty-eight patients (24%) received
Data Loading...
